Report #2898629

Received Jun 2, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: AR
Recovered: Unknown
Vaccinated: May 15, 2026
Onset: May 15, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	UNK	KR94A	—

Symptoms (1)

Product preparation issue

Symptom narrative

Arexvy adjuvant only administration; Arexvy adjuvant only administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a male patient who received RSVPreF3 adjuvanted (Arexvy) suspension for injection (batch number KR94A with expiry date 23-JAN-2027) for prophylaxis. On 15-MAY-2026, the patient received Arexvy. On 15-MAY-2026, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: Arexvy adjuvant only administration) and inappropriate dose of vaccine administered (Verbatim: Arexvy adjuvant only administration). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 29-MAY-2026 Pharmacist wanted to know how to proceed. The vaccine administration facility was the same as primary reporter.